Inovio Pharmaceuticals Inc (INO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $262.23M
Last updated: Nov 17, 2026 at 4:43 PM ET
Inovio Pharmaceuticals Inc (INO) Statistics
Inovio Pharmaceuticals (INO) has a market cap of $262.23M and an enterprise value of $215.27M. It kept -30457.17% of revenue as net income over the last 12 months. Its share count is up 89.07% from a year earlier.
Total Valuation
Enterprise value is 17.91% below the market cap, as cash exceeds debt.
| Market Cap | $262.23M |
|---|---|
| Enterprise Value | $215.27M |
| Latest price (Nov 17, 2026) | $1.63 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 537.9x. Its year-end P/S ranged from 9.2x to 415.3x from 2016 to 2024.
| P/S Ratio | 537.9x |
|---|---|
| Forward P/S | 700.2x |
Price Statistics
The stock is down 20.49% over 52 weeks and trades 36.97% above its 50-day average.
| Beta (1Y) | 0.56 |
|---|---|
| 52-Week Change | -20.49% |
| 1-Month Change | +63.00% |
| 3-Month Change | +25.38% |
| 6-Month Change | +33.61% |
| 5-Year Change | -99.30% |
| 10-Year Change | -99.22% |
| Total Return (1Y) | -20.49% |
| Total Return (3Y CAGR) | -31.84% |
| Total Return (5Y CAGR) | -54.82% |
| Return vs SPY (1Y) | -25.32% |
| Max Drawdown (1Y) | -76.83% |
| Max Drawdown (3Y) | -95.66% |
| Sharpe Ratio (1Y) | -0.09 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $1.19 |
| 200-Day Average | $1.26 |
| 52-Week Range | $0.56 to $2.72 |
| RSI (14 Days) | 60.0 |
| Average Volume (20 Days) | 27.74M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.57x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.57x |
|---|---|
| Quick Ratio | 0.57x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -118.29% |
|---|---|
| ROA (5Y Average) | -85.92% |
| Asset Turnover | 0.00x |
Scores
INO has an Altman Z-Score of -47.32, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -47.32 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $233.56K over the last 12 months is up 28.09% from the 12 months before.
| Revenue | $233.56K |
|---|---|
| Revenue Growth (YoY) | +28.09% |
| Gross Profit | -$455.15K |
| Operating Income | -$77.58M |
| Pretax Income | -$65.91M |
| Net Income | -$71.14M |
| EBITDA | -$62.36M |
| EBIT | -$65.33M |
| Reported EPS (TTM) | -$0.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $46.96M |
|---|---|
| Total Debt | $0 |
| Net Cash | $46.96M |
| Net Cash Per Share | $0.48 |
| Working Capital | -$38.03M |
| Shareholder Equity | -$33.92M |
| Total Assets | $60.14M |
| Total Liabilities | $94.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$74.28M |
|---|---|
| FCF Per Share | -$0.68 |
| Depreciation and Amortization | $2.98M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -33214.90%.
| Gross Margin | -194.88% |
|---|---|
| Operating Margin | -33214.90% |
| Pretax Margin | -28219.46% |
| Net Margin | -30457.17% |
| EBITDA Margin | -26699.53% |
| EBIT Margin | -27973.61% |
Growth
Revenue fell 81.47% a year over 3 years.
| Revenue Growth (3Y CAGR) | -81.47% |
|---|---|
| Revenue Growth (5Y CAGR) | -61.18% |
| Book Value Per Share Growth (2Y CAGR) | -90.01% |
| Tangible Book Per Share Growth (2Y CAGR) | -90.01% |
Dividends and Yields
INO does not pay a dividend.
| Buyback Yield | -42.24% |
|---|---|
| Shareholder Yield | -42.24% |
Stock Splits
The last split was a 1-for-12 reverse split on Jan 25, 2024.
| Last Split Date | Jan 25, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Peer Position
Against 5 similar companies, INO has the highest P/S.
P/S RatioPeer median 4.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 537.9x vs 4.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +28.09% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 3051.14% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3051.14% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INO
What is INO's market cap?
Inovio Pharmaceuticals has a market cap of $262.23M. Its enterprise value, which adds debt and subtracts cash, is $215.27M.
How many shares of INO are outstanding?
Inovio Pharmaceuticals has 98.63M shares outstanding. The count is up 89.07% from a year earlier.
Does INO pay a dividend?
No. Inovio Pharmaceuticals does not pay a dividend.
How much debt does INO have?
Inovio Pharmaceuticals has $0 of total debt and $46.96M of cash and equivalents, a net cash position of $46.96M.
INO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors